BNTC Benitec Biopharma Inc
Price (delayed)
$12.55
Market cap
$294.32M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.01
Enterprise value
$216.08M
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It
Highlights
The company's EPS has surged by 91% YoY and by 67% QoQ
The company's quick ratio has surged by 70% QoQ
The company's revenue has shrunk by 100% YoY
The gross profit has dropped by 100% year-on-year
Key stats
What are the main financial stats of BNTC
Market
Valuations
Earnings
Shares outstanding
23.45M
Market cap
$294.32M
Enterprise value
$216.08M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.84
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$24.09M
Net income
-$21.42M
EBIT
-$20.9M
EBITDA
-$20.55M
Free cash flow
-$21.94M
Per share
Balance sheet
Liquidity
EPS
-$0.01
EPS diluted
-$0.01
Free cash flow per share
-$0.99
Book value per share
$3.27
Revenue per share
$0
TBVPS
$3.58
Total assets
$79.07M
Total liabilities
$3.13M
Debt
$137,000
Equity
$75.94M
Working capital
$75.62M
Debt to equity
0
Current ratio
25.48
Quick ratio
25.37
Net debt/EBITDA
3.81
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-41%
Return on equity
-44.3%
Return on invested capital
N/A
Return on capital employed
-27.5%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BNTC stock price
How has the Benitec Biopharma stock price performed over time
Intraday
4.41%
1 week
-10.42%
1 month
-1.26%
1 year
136.79%
YTD
-0.63%
QTD
-3.54%
Financial performance
How have Benitec Biopharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$24.09M
Net income
-$21.42M
Gross margin
N/A
Net margin
N/A
The company's revenue has shrunk by 100% YoY
The gross profit has dropped by 100% year-on-year
The operating income has declined by 11% year-on-year and by 8% since the previous quarter
BNTC's net income is down by 2.7% since the previous quarter
Growth
What is Benitec Biopharma's growth rate over time
Valuation
What is Benitec Biopharma stock price valuation
P/E
N/A
P/B
3.84
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS has surged by 91% YoY and by 67% QoQ
BNTC's P/B is 84% above its last 4 quarters average of 2.0 and 15% above its 5-year quarterly average of 3.2
The equity has grown by 18% from the previous quarter
The company's revenue has shrunk by 100% YoY
Efficiency
How efficient is Benitec Biopharma business performance
Benitec Biopharma's return on equity has surged by 79% YoY and by 29% QoQ
Benitec Biopharma's ROA has soared by 72% YoY and by 25% from the previous quarter
Dividends
What is BNTC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BNTC.
Financial health
How did Benitec Biopharma financials performed over time
The company's quick ratio has surged by 70% QoQ
BNTC's current ratio has surged by 70% since the previous quarter
The debt is 100% less than the equity
The debt to equity has plunged by 100% YoY
The debt has plunged by 68% YoY and by 35% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.